Gedeon Richter receives registration for Memantine-Richter dementia treatment
Pharmaceutical firm Gedeon Richter has secured regulatory registration for Memantine-Richter, a tablet formulation indicated for moderate to severe Alzheimer's disease.
Gedeon Richter has received registration for its Memantine-Richter medication, which utilizes memantine hydrochloride as the active ingredient. The drug is classified for the treatment of dementia symptoms associated with Alzheimer's disease, specifically targeting moderate to severe stages of the condition.
The pharmaceutical action of memantine involves the modulation of glutamatergic neurotransmission. By acting as an uncompetitive antagonist of NMDA receptors, the medication seeks to prevent neuronal dysfunction caused by elevated levels of glutamate, thereby supporting cognitive processes and daily patient functionality.
The 10 mg film-coated tablets are intended for administration under medical supervision. Usage is contraindicated for patients with severe liver impairment and is not recommended during pregnancy or breastfeeding. Clinical guidelines suggest monitoring is essential for patients with pre-existing conditions such as epilepsy or cardiovascular issues.
This registration expands Gedeon Richter's portfolio in the neurology sector, providing a targeted treatment option for clinicians managing progressive neurodegenerative decline.